Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponsegromab plus first-line chemotherapy for cachexia in metastatic pancreatic ductal adenocarcinoma
MOH_2025-08-27_014302Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ponsegromab in cancer anorexia-cachexia syndrome (CACS) and pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Pfizer. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ponsegromab
03
Conditions
cancer anorexia-cachexia syndrome (CACS)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2025-08-27_014302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-08-27_014302.